Matches in SemOpenAlex for { <https://semopenalex.org/work/W2129486980> ?p ?o ?g. }
- W2129486980 endingPage "43" @default.
- W2129486980 startingPage "35" @default.
- W2129486980 abstract "Objective5-azacytidine (azacytidine), a DNA hypomethylating agent, was recently approved as the first therapeutic agent for the treatment of myelodysplastic syndromes. The present subcutaneous dosing schedule, 75 mg/m2 for 7/28 days, is based on early clinical studies and may constitute a practical problem for patients. The present in vitro study aimed at evaluating the pharmacodynamics of azacytidine, thereby providing a rationale for clinical dose-finding studies.MethodsP39 cells were incubated with 0.1, 0.5, and 1 μM azacytidine daily for 24, 48, and 72 hours, followed by 48 hours in drug-free medium. The effects of azacytidine on cell growth, proliferation, apoptosis, cell cycle status, and promoter methylation of E-cadherin, ER, and HIC genes were studied.ResultsAzacytidine decreased cell growth and proliferation, increased apoptosis, and affected cell cycle status in a dose-dependent manner. However, the exposure time, 24 to 72 hours, at doses between 0.5 and 1 μM, did not significantly affect any of these variables. Using first-order exponential pharmacokinetic model, we found that the effect of 1, 2, or 3 μM over 24 hours did not differ from that of 0.5 to 1 μM given over 48 to 72 hours. Induction of promoter hypomethylation was observed already after 24 hours of exposure with ≥0.5 μM azacytidine with no clear dose-effect relationship.ConclusionOur results indicate that optimal cellular effects of azacytidine might be achieved by shorter exposure times. The model provides information about the relation between azacytidine dose intensity and exposure time on malignant myeloid cells, which could serve as a rationale for further clinical development of practical, safe, and cost-effective dosing schedules. 5-azacytidine (azacytidine), a DNA hypomethylating agent, was recently approved as the first therapeutic agent for the treatment of myelodysplastic syndromes. The present subcutaneous dosing schedule, 75 mg/m2 for 7/28 days, is based on early clinical studies and may constitute a practical problem for patients. The present in vitro study aimed at evaluating the pharmacodynamics of azacytidine, thereby providing a rationale for clinical dose-finding studies. P39 cells were incubated with 0.1, 0.5, and 1 μM azacytidine daily for 24, 48, and 72 hours, followed by 48 hours in drug-free medium. The effects of azacytidine on cell growth, proliferation, apoptosis, cell cycle status, and promoter methylation of E-cadherin, ER, and HIC genes were studied. Azacytidine decreased cell growth and proliferation, increased apoptosis, and affected cell cycle status in a dose-dependent manner. However, the exposure time, 24 to 72 hours, at doses between 0.5 and 1 μM, did not significantly affect any of these variables. Using first-order exponential pharmacokinetic model, we found that the effect of 1, 2, or 3 μM over 24 hours did not differ from that of 0.5 to 1 μM given over 48 to 72 hours. Induction of promoter hypomethylation was observed already after 24 hours of exposure with ≥0.5 μM azacytidine with no clear dose-effect relationship. Our results indicate that optimal cellular effects of azacytidine might be achieved by shorter exposure times. The model provides information about the relation between azacytidine dose intensity and exposure time on malignant myeloid cells, which could serve as a rationale for further clinical development of practical, safe, and cost-effective dosing schedules." @default.
- W2129486980 created "2016-06-24" @default.
- W2129486980 creator A5017390964 @default.
- W2129486980 creator A5018387509 @default.
- W2129486980 creator A5031248010 @default.
- W2129486980 creator A5033723505 @default.
- W2129486980 creator A5048471852 @default.
- W2129486980 date "2006-01-01" @default.
- W2129486980 modified "2023-10-02" @default.
- W2129486980 title "A pharmacodynamic study of 5-azacytidine in the P39 cell line" @default.
- W2129486980 cites W1575135707 @default.
- W2129486980 cites W187238933 @default.
- W2129486980 cites W1879966002 @default.
- W2129486980 cites W1891825979 @default.
- W2129486980 cites W1964050328 @default.
- W2129486980 cites W1965115751 @default.
- W2129486980 cites W2005486326 @default.
- W2129486980 cites W2022733644 @default.
- W2129486980 cites W2037179719 @default.
- W2129486980 cites W2042166539 @default.
- W2129486980 cites W2062093164 @default.
- W2129486980 cites W2062145659 @default.
- W2129486980 cites W2077719775 @default.
- W2129486980 cites W2088633051 @default.
- W2129486980 cites W2106292925 @default.
- W2129486980 cites W2106584820 @default.
- W2129486980 cites W2108552793 @default.
- W2129486980 cites W2109895173 @default.
- W2129486980 cites W2116476764 @default.
- W2129486980 cites W2161787721 @default.
- W2129486980 cites W2170131366 @default.
- W2129486980 cites W2210620858 @default.
- W2129486980 cites W2354344320 @default.
- W2129486980 cites W4253876192 @default.
- W2129486980 doi "https://doi.org/10.1016/j.exphem.2005.09.007" @default.
- W2129486980 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/16413389" @default.
- W2129486980 hasPublicationYear "2006" @default.
- W2129486980 type Work @default.
- W2129486980 sameAs 2129486980 @default.
- W2129486980 citedByCount "23" @default.
- W2129486980 countsByYear W21294869802013 @default.
- W2129486980 countsByYear W21294869802014 @default.
- W2129486980 countsByYear W21294869802015 @default.
- W2129486980 countsByYear W21294869802016 @default.
- W2129486980 countsByYear W21294869802017 @default.
- W2129486980 countsByYear W21294869802020 @default.
- W2129486980 countsByYear W21294869802022 @default.
- W2129486980 crossrefType "journal-article" @default.
- W2129486980 hasAuthorship W2129486980A5017390964 @default.
- W2129486980 hasAuthorship W2129486980A5018387509 @default.
- W2129486980 hasAuthorship W2129486980A5031248010 @default.
- W2129486980 hasAuthorship W2129486980A5033723505 @default.
- W2129486980 hasAuthorship W2129486980A5048471852 @default.
- W2129486980 hasBestOaLocation W21294869801 @default.
- W2129486980 hasConcept C104317684 @default.
- W2129486980 hasConcept C111113717 @default.
- W2129486980 hasConcept C112705442 @default.
- W2129486980 hasConcept C121608353 @default.
- W2129486980 hasConcept C126322002 @default.
- W2129486980 hasConcept C1491633281 @default.
- W2129486980 hasConcept C150194340 @default.
- W2129486980 hasConcept C190283241 @default.
- W2129486980 hasConcept C190727270 @default.
- W2129486980 hasConcept C2776012956 @default.
- W2129486980 hasConcept C2776239401 @default.
- W2129486980 hasConcept C2780235182 @default.
- W2129486980 hasConcept C29537977 @default.
- W2129486980 hasConcept C502942594 @default.
- W2129486980 hasConcept C55493867 @default.
- W2129486980 hasConcept C62112901 @default.
- W2129486980 hasConcept C71924100 @default.
- W2129486980 hasConcept C86803240 @default.
- W2129486980 hasConcept C98274493 @default.
- W2129486980 hasConceptScore W2129486980C104317684 @default.
- W2129486980 hasConceptScore W2129486980C111113717 @default.
- W2129486980 hasConceptScore W2129486980C112705442 @default.
- W2129486980 hasConceptScore W2129486980C121608353 @default.
- W2129486980 hasConceptScore W2129486980C126322002 @default.
- W2129486980 hasConceptScore W2129486980C1491633281 @default.
- W2129486980 hasConceptScore W2129486980C150194340 @default.
- W2129486980 hasConceptScore W2129486980C190283241 @default.
- W2129486980 hasConceptScore W2129486980C190727270 @default.
- W2129486980 hasConceptScore W2129486980C2776012956 @default.
- W2129486980 hasConceptScore W2129486980C2776239401 @default.
- W2129486980 hasConceptScore W2129486980C2780235182 @default.
- W2129486980 hasConceptScore W2129486980C29537977 @default.
- W2129486980 hasConceptScore W2129486980C502942594 @default.
- W2129486980 hasConceptScore W2129486980C55493867 @default.
- W2129486980 hasConceptScore W2129486980C62112901 @default.
- W2129486980 hasConceptScore W2129486980C71924100 @default.
- W2129486980 hasConceptScore W2129486980C86803240 @default.
- W2129486980 hasConceptScore W2129486980C98274493 @default.
- W2129486980 hasIssue "1" @default.
- W2129486980 hasLocation W21294869801 @default.
- W2129486980 hasOpenAccess W2129486980 @default.
- W2129486980 hasPrimaryLocation W21294869801 @default.
- W2129486980 hasRelatedWork W2113956050 @default.
- W2129486980 hasRelatedWork W2129486980 @default.